| Bioxyne Limited (BXN) ORDINARY FULLY PAID |
Consumer Staple |
$197 |
Application for quotation of securities - BXN
|
15 Dec 2025 9:13AM |
$0.039 |
$0.086 |
risen by
120.51%
|
|
| Mirrabooka Investments Limited (MIR) ORDINARY FULLY PAID |
Financials |
$537 |
Weekly Estimated NTA as at 12 December 2025
|
15 Dec 2025 9:13AM |
$3.140 |
$2.400 |
fallen by
23.57%
|
|
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$10,031 |
Update - Notification of buy-back - LNW
|
15 Dec 2025 9:12AM |
$151.410 |
$123.560 |
fallen by
18.39%
|
|
| Pengana Capital Group Limited (PCG) ORDINARY FULLY PAID |
Financials |
$74 |
Monthly Funds Under Management - 30 November 2025
|
15 Dec 2025 9:12AM |
$0.660 |
$0.755 |
risen by
14.39%
|
|
PCG - Price-sensitive ASX Announcement
Full Release
Key Points
- Pengana Capital Group Limited (ASX: PCG) reported funds under management (FUM) as of 30 November 2025 at $3,856.48 million.
- The FUM increased from $3,840.24 million at 31 October 2025.
- The announcement was approved by Paula Ferrao, Company Secretary.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aristocrat Leisure Limited (ALL) ORDINARY FULLY PAID |
Consumer Discretionary |
$32,192 |
2025 Annual Report and date of 2026 Annual General Meeting
|
15 Dec 2025 9:12AM |
$56.710 |
$53.380 |
fallen by
5.87%
|
|
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$290 |
Update - Notification of buy-back - AMH
|
15 Dec 2025 9:12AM |
$1.035 |
$0.920 |
fallen by
11.11%
|
|
| Mt Malcolm Mines NL (M2M) ORDINARY FULLY PAID |
Materials |
$3 |
M2M Secures 500k TPA Processing Mill
|
15 Dec 2025 9:12AM |
$0.012 |
$0.006 |
fallen by
50%
|
|
M2M - Price-sensitive ASX Announcement
Full Release
Key Points
- Mt Malcolm Mines NL (M2M) has secured a 500,000 tpa carbon-in-leach (CIL) gold processing plant.
- The plant components were acquired from Absolute West Pty Ltd for $550,000 plus GST.
- A deposit of $100,000 is payable on execution, with the balance in two instalments upon delivery.
- The acquisition includes major components like crushing, milling, power, pumps, coarse gold circuit, and elution extraction.
- This positions M2M as one of few juniors with such processing capabilities in a prolific gold region.
- The plant is relocation-ready and can be operational within 12–15 months after the final investment decision.
- The acquisition enables future self-processing and generates cash flow through toll-milling.
- M2M aims to become a self-sufficient gold producer in Leonora, where processing capacity is limited.
- Discussions are underway for a feasibility study on developing a fully functional processing facility.
- A detailed relocation, refurbishment, and commissioning plan will be announced in upcoming months.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kip McGrath Education Centres Limited (KME) ORDINARY FULLY PAID |
Consumer Discretionary |
$27 |
Update - Notification of buy-back - KME
|
15 Dec 2025 9:12AM |
$0.570 |
$0.520 |
fallen by
8.77%
|
|
| Morphic Ethical Equities Fund Limited (MEC) ORDINARY FULLY PAID |
Financials |
$40 |
Update - Notification of buy-back - MEC
|
15 Dec 2025 9:11AM |
$1.165 |
$1.325 |
risen by
13.73%
|
|
| Connexion Mobility Ltd (CXZ) ORDINARY FULLY PAID |
Information Technology |
$17 |
Update - Notification of buy-back - CXZ
|
15 Dec 2025 9:11AM |
$0.026 |
$0.024 |
fallen by
7.69%
|
|
| EV Resources Limited (EVR) ORDINARY FULLY PAID |
Materials |
$21 |
Maiden Drilling Set to Commence at Los Lirios Project
|
15 Dec 2025 9:11AM |
$0.009 |
$0.007 |
fallen by
22.22%
|
|
EVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Maiden drill program to commence in early January 2026.
- Fully funded program targeting high-grade antimony under historical workings.
- Phase 1 comprises 1,500-2,000 meters of diamond drilling.
- Aim to deliver maiden JORC resource by Q3 2026.
- Parallel advancement at Los Lirios and Tecomatlán Plant for production readiness.
- Part of a larger 2026 exploration campaign to unlock full scale potential.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Prescient Therapeutics Limited (PTX) ORDINARY FULLY PAID |
Health Care |
$74 |
PTX secures EU Authorisation to commence PTX-100 Trial
|
15 Dec 2025 9:10AM |
$0.089 |
$0.070 |
fallen by
21.35%
|
|
PTX - Price-sensitive ASX Announcement
Full Release
Key Points
- Prescient Therapeutics Limited secures EU authorisation to commence the PTX-100 trial.
- The trial targets patients with relapsed/refractory Cutaneous T-cell Lymphoma (CTCL) in Italy.
- PTX-100 is a first-in-class therapy targeting cancer growth pathways.
- The trial is advancing into Phase 2a with recruitment beginning in Europe.
- The European Clinical Trials Information System (CTIS) granted the authorisation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$96 |
Update - Notification of buy-back - CAM
|
15 Dec 2025 9:10AM |
$0.690 |
$0.680 |
fallen by
1.45%
|
|
| Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID |
Health Care |
$63 |
Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial
|
15 Dec 2025 9:09AM |
$0.265 |
$0.260 |
fallen by
1.89%
|
|
CYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Patient enrolment completed for Phase 2 aGvHD clinical trial.
- 65 participants enrolled across the USA, Europe, and Australia.
- Participants received either steroids plus CYP-001 or steroids plus placebo.
- Primary evaluation period to conclude in March 2026, results expected by June 2026.
- CYP-001 is designed to improve response rates and survival in aGvHD.
- Phase 1 trial showed 87% overall response and no serious adverse events.
- CYP-001 has Orphan Drug Designation by the US FDA for aGvHD treatment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$10,031 |
LNW Form 3-Amendment (Fine Capital)
|
15 Dec 2025 9:09AM |
$151.410 |
$123.560 |
fallen by
18.39%
|
|
| Intelligent Monitoring Group Limited (IMB) ORDINARY FULLY PAID |
Industrials |
$235 |
Trading Halt
|
15 Dec 2025 9:08AM |
$0.640 |
$0.570 |
fallen by
10.94%
|
|
IMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Intelligent Monitoring Group Limited.
- Pending announcement regarding proposed equity raising.
- Halt effective from 15 December 2025.
- Trading expected to resume on 17 December 2025 or upon announcement.
- No known reasons to deny the trading halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nova Minerals Limited (NVA) ORDINARY FULLY PAID |
Materials |
$350 |
Suspension from Quotation
|
15 Dec 2025 9:08AM |
$1.030 |
$0.765 |
fallen by
25.73%
|
|
NVA - Price-sensitive ASX Announcement
Full Release
Key Points
- Nova Minerals Limited requests voluntary suspension of its securities.
- The suspension is under ASX Listing Rule 17.2.
- Suspension is due to pending announcement on proposed capital raising.
- Trading halt was requested prior on 11 December 2025.
- Expected end of suspension on 17 December 2025.
- No known impediments to granting the suspension.
- Request authorized by the Executive Directors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Meridian Energy Limited (MEZ) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Utilities |
$12,687 |
Financial assistance in connection with FY26 Equity Plan
|
15 Dec 2025 9:08AM |
$4.800 |
$4.790 |
fallen by
0.21%
|
|
| Brazilian Rare Earths Limited (BRE) ORDINARY FULLY PAID |
Materials |
$1,432 |
Amargosa Bauxite Presentation
|
15 Dec 2025 9:08AM |
$4.000 |
$5.110 |
risen by
27.75%
|
|
| Light & Wonder Inc. (LNW) CHESS DEPOSITARY INTERESTS 1:1 |
Consumer Discretionary |
$10,031 |
LNW Form 4-Amendment (Fine Capital)
|
15 Dec 2025 9:07AM |
$151.410 |
$123.560 |
fallen by
18.39%
|
|
| BKI Investment Company Limited (BKI) ORDINARY FULLY PAID |
Financials |
$1,408 |
BKI 12 December 2025 Weekly NTA
|
15 Dec 2025 9:06AM |
$1.705 |
$1.745 |
risen by
2.35%
|
|
| Epiminder Limited (EPI) ORDINARY FULLY PAID |
Health Care |
$61 |
Change of Director's Interest Notice DO
|
15 Dec 2025 9:06AM |
$1.150 |
$0.350 |
fallen by
69.57%
|
|
| Orthocell Limited (OCC) ORDINARY FULLY PAID |
Health Care |
$203 |
Remplir Regulatory Application for US$750m EU-UK Market
|
15 Dec 2025 9:05AM |
$1.020 |
$0.745 |
fallen by
26.96%
|
|
OCC - Price-sensitive ASX Announcement
Full Release
Key Points
- Orthocell submits regulatory application to BSI for EU and UK markets.
- The EU and UK nerve repair market represents a US$750 million opportunity.
- Application supported by 81.1% treatment success rate in real-world evidence study.
- Expected 'CE' and 'UKCA' certification by 3Q CY26.
- Orthocell has a strong balance sheet with approximately $50 million in cash.
- Orthocell plans to utilize in-country distributors and key opinion leaders for market strategy.
- Remplir already approved in various countries including the US, Australia, and Hong Kong.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$1,681 |
FDA approves DAYBUE STIX (trofinetide), powder formulation
|
15 Dec 2025 9:05AM |
$19.010 |
$13.310 |
fallen by
29.98%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA approved DAYBUE STIX, a new powder formulation of trofinetide.
- DAYBUE STIX is designed for Rett syndrome patients aged two years and older.
- The new formulation offers flexible dosing options by mixing with liquids.
- Neuren Pharmaceuticals will receive royalties from the sales.
- Approval was based on bioequivalence with the original DAYBUE oral solution.
- DAYBUE STIX expected to be available in early 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$177 |
CFO transition
|
15 Dec 2025 9:04AM |
$0.200 |
$0.170 |
fallen by
15%
|
|